{"version":"1.0","type":"link","title":"Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours.","author_name":"Bashi AC 외","author_url":"https://prs-insight.online/author/Bashi%20AC","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/81978","thumbnail_width":1200,"thumbnail_height":630}